Cardama, G.A.; Bucci, P.L.; Lemos, J.S.; Llavona, C.; Benavente, M.A.; Hellmén, E.; Fara, M.L.; Medrano, E.; Spitzer, E.; Demarco, I.A.;
et al. In Silico and In Vitro Evaluation of Bevacizumab Biosimilar MB02 as an Antitumor Agent in Canine Mammary Carcinoma. Animals 2023, 13, 2507.
https://doi.org/10.3390/ani13152507
AMA Style
Cardama GA, Bucci PL, Lemos JS, Llavona C, Benavente MA, Hellmén E, Fara ML, Medrano E, Spitzer E, Demarco IA,
et al. In Silico and In Vitro Evaluation of Bevacizumab Biosimilar MB02 as an Antitumor Agent in Canine Mammary Carcinoma. Animals. 2023; 13(15):2507.
https://doi.org/10.3390/ani13152507
Chicago/Turabian Style
Cardama, Georgina A., Paula L. Bucci, Jesús S. Lemos, Candela Llavona, Micaela A. Benavente, Eva Hellmén, MarÃa Laura Fara, Eduardo Medrano, Eduardo Spitzer, Ignacio A. Demarco,
and et al. 2023. "In Silico and In Vitro Evaluation of Bevacizumab Biosimilar MB02 as an Antitumor Agent in Canine Mammary Carcinoma" Animals 13, no. 15: 2507.
https://doi.org/10.3390/ani13152507
APA Style
Cardama, G. A., Bucci, P. L., Lemos, J. S., Llavona, C., Benavente, M. A., Hellmén, E., Fara, M. L., Medrano, E., Spitzer, E., Demarco, I. A., Sabella, P., Garona, J., & Alonso, D. F.
(2023). In Silico and In Vitro Evaluation of Bevacizumab Biosimilar MB02 as an Antitumor Agent in Canine Mammary Carcinoma. Animals, 13(15), 2507.
https://doi.org/10.3390/ani13152507
